(BEAM) Beam Therapeutics - Ratings and Ratios
Base Editing Therapies
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 86.3% |
| Value at Risk 5%th | 122% |
| Relative Tail Risk | -14.11% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.55 |
| Alpha | -4.92 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.496 |
| Beta | 1.632 |
| Beta Downside | 1.758 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.20% |
| Mean DD | 46.08% |
| Median DD | 47.56% |
Description: BEAM Beam Therapeutics January 14, 2026
Beam Therapeutics Inc. (NASDAQ: BEAM) is a Cambridge-based biotech focused on precision genetic medicines using base-editing and CRISPR-derived platforms. Its pipeline centers on in-vivo liver-targeted LNP programs (BEAM-301 for glycogen storage disease 1a, BEAM-302 for severe alpha-1 antitrypsin deficiency) and a hematology program (BEAM-101 for sickle-cell disease), with additional early-stage assets such as the anti-CD117 antibody BEAM-103, a cell-therapy candidate BEAM-104, and ex-vivo CAR-T candidates (e.g., BEAM-201).
Strategic collaborations amplify its R&D reach: a multi-year agreement with Pfizer funds in-vivo base-editing projects for rare liver, muscle, and CNS disorders; a preclinical deal with Apellis targets complement-system genes; partnerships with Verve (cardiovascular), Sana (CRISPR Cas12b for cell therapy), and Orbital Therapeutics (RNA design). These alliances collectively provide non-dilutive capital and access to complementary expertise.
Key financial metrics (Q2 2024): cash and equivalents ≈ $620 million, giving a runway of roughly 18 months at current burn; market capitalization ≈ $2.3 billion; and a recent Phase 1/2 read-out for BEAM-101 showed a ≈ 50 % reduction in hemolysis biomarkers and a favorable safety profile, positioning the program for a Phase 2/3 launch decision in 2025. The broader gene-editing sector is benefiting from expanding FDA guidance on genome-editing therapies and increasing investor appetite for high-precision, potentially curative modalities.
Given the early-stage nature of most assets and the reliance on partnership funding, valuation hinges heavily on the timing and outcomes of BEAM-101 and the liver-targeted LNP programs; a delay or adverse safety signal would materially downgrade the upside.
For a deeper quantitative assessment, see the ValueRay analysis of BEAM.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -414.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -14.46 > 1.0 |
| NWC/Revenue: 1644 % < 20% (prev 222.9%; Δ 1422 % < -1%) |
| CFO/TA -0.26 > 3% & CFO -338.2m > Net Income -414.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.6m) vs 12m ago 24.46% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.49% > 50% (prev 29.85%; Δ -25.36% > 0%) |
| Interest Coverage Ratio: -19.47 > 6 (EBITDA TTM -430.1m / Interest Expense TTM 23.2m) |
Altman Z'' -8.32
| A: 0.70 (Total Current Assets 1.10b - Total Current Liabilities 182.6m) / Total Assets 1.31b |
| B: -1.44 (Retained Earnings -1.89b / Total Assets 1.31b) |
| C: -0.36 (EBIT TTM -452.2m / Avg Total Assets 1.24b) |
| D: -5.47 (Book Value of Equity -1.89b / Total Liabilities 345.1m) |
| Altman-Z'' Score: -8.32 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 55.7m/349.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.85 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.16 (Revenue 55.7m / 349.6m) |
| TATA: -0.06 (NI -414.6m - CFO -338.2m) / TA 1.31b) |
| Beneish M-Score: cannot calculate (missing components) |
ValueRay F-Score (Strict, 0-100) 25.07
| 1. Piotroski: 0.0pt |
| 2. FCF Yield: -13.80% |
| 3. FCF Margin: data missing |
| 4. Debt/Equity: 0.16 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -48.60% |
| 7. RoE: -42.86% |
| 8. Revenue Trend: -32.24% |
| 9. EPS Trend: data missing |
What is the price of BEAM shares?
Over the past week, the price has changed by -0.86%, over one month by +10.27%, over three months by +14.85% and over the past year by +18.49%.
Is BEAM a buy, sell or hold?
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.5 | 48.1% |
| Analysts Target Price | 45.5 | 48.1% |
| ValueRay Target Price | 31.1 | 1.2% |
BEAM Fundamental Data Overview January 24, 2026
P/B = 3.268
Revenue TTM = 55.7m USD
EBIT TTM = -452.2m USD
EBITDA TTM = -430.1m USD
Long Term Debt = 151.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 151.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.55b USD (3.48b + Debt 151.4m - CCE 1.07b)
Interest Coverage Ratio = -19.47 (Ebit TTM -452.2m / Interest Expense TTM 23.2m)
EV/FCF = -7.25x (Enterprise Value 2.55b / FCF TTM -352.4m)
FCF Yield = -13.80% (FCF TTM -352.4m / Enterprise Value 2.55b)
FCF Margin = -632.6% (FCF TTM -352.4m / Revenue TTM 55.7m)
Net Margin = -744.4% (Net Income TTM -414.6m / Revenue TTM 55.7m)
Gross Margin = -639.3% ((Revenue TTM 55.7m - Cost of Revenue TTM 411.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.95 (Enterprise Value 2.55b / Total Assets 1.31b)
Interest Expense / Debt = 7.20% (Interest Expense 10.9m / Debt 151.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -357.2m (EBIT -452.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.02 (Total Current Assets 1.10b / Total Current Liabilities 182.6m)
Debt / Equity = 0.16 (Debt 151.4m / totalStockholderEquity, last quarter 966.0m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -116.5m / EBITDA -430.1m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -116.5m / FCF TTM -352.4m)
Total Stockholder Equity = 967.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.41% (Net Income -414.6m / Total Assets 1.31b)
RoE = -42.86% (Net Income TTM -414.6m / Total Stockholder Equity 967.4m)
RoCE = -40.42% (EBIT -452.2m / Capital Employed (Equity 967.4m + L.T.Debt 151.4m))
RoIC = -36.93% (negative operating profit) (NOPAT -357.2m / Invested Capital 967.4m)
WACC = 11.67% (E(3.48b)/V(3.63b) * Re(11.93%) + D(151.4m)/V(3.63b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 11.93% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -352.4m)
Revenue Correlation: -32.24 | Revenue CAGR: -35.79% | SUE: N/A | # QB: 0
Additional Sources for BEAM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle